Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This entry represents a long non-coding RNA gene designated "novel transcript, antisense to VIPR2" (Ensembl: ENSG00000287184), which is transcribed from a region opposite the coding sequence for the vasoactive intestinal peptide receptor 2 (VIPR2)[3]. lncRNAs in antisense orientation may regulate adjacent coding genes at the RNA level, but there is currently no direct evidence for this transcript having a recognized molecular function, disease association, or suitability as a drug target[3]. There is also no established abbreviation, aliases, or known interacting compounds. This indicates that ENSG00000287184 is unlikely to be a relevant target for pharmacological intervention or biomarker studies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to VIPR2.